{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005016","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.751947+00:00","generated_at":"2026-05-28T03:41:06.512708+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cabaletta Bio reports $164M cash, expands rese-cel trials into MS, MG, PV; FDA meeting planned 1H25","bullets":["Unaudited cash $164M as of Dec 31, 2024; funds operations into H1 2026.","21 patients enrolled across 44 RESET sites in US/Europe; safety data: 90% no CRS/grade 1, 90% no ICANS.","First patients enrolled in RESET-PV (no preconditioning) and RESET-MG; RESET-MS IND cleared with Fast Track.","Expanded CDMO agreement with Lonza for clinical supply from H2 2025.","Plans to meet FDA in 1H 2025 to align on registrational trial designs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005016","json":"https://secwatch.observer/filing/0001193125-25-005016.json","markdown":"https://secwatch.observer/filing/0001193125-25-005016.md","text":"https://secwatch.observer/filing/0001193125-25-005016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525005016/0001193125-25-005016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525005016/d781872d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:41:06.512708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}